INFANRIX- diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed suspension
GlaxoSmithKline Biologicals SA

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use INFANRIX safely and effectively. See full prescribing information for INFANRIX.
INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Suspension for Intramuscular Injection
Initial U.S. Approval: 1997

INDICATIONS AND USAGE
INFANRIX is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the 7th birthday). (1)

DOSAGE AND ADMINISTRATION
A 0.5-mL intramuscular injection given as a 5-dose series: (2.2)

• One dose each at 2, 4, and 6 months of age.
• One booster dose at 15 to 20 months of age and another booster dose at 4 to 6 years of age.

DOSAGE FORMS AND STRENGTHS
Single-dose vials and single-dose, prefilled syringes containing a 0.5-mL suspension for injection. (3)

CONTRAINDICATIONS
• Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or to any component of INFANRIX. (4.1)
• Encephalopathy within 7 days of administration of a previous pertussis-containing vaccine. (4.2)
• Progressive neurologic disorders. (4.3)

WARNINGS AND PRECAUTIONS
• If Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give INFANRIX should be based on potential benefits and risks. (5.1)
• The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions. (5.2)
• Syncope (fainting) can occur in association with administration of injectable vaccines, including INFANRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope. (5.3)
• If temperature ≥105°F, collapse or shock-like state, or persistent, inconsolable crying lasting ≥3 hours have occurred within 48 hours after receipt of a pertussis-containing vaccine, or if seizures have occurred within 3 days after receipt of a pertussis-containing vaccine, the decision to give INFANRIX should be based on potential benefits and risks. (5.4)
• For children at higher risk for seizures, an antipyretic may be administered at the time of vaccination with INFANRIX. (5.5)
• Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including INFANRIX, to infants born prematurely should be based on consideration of the individual infant’s medical status, and the potential benefits and possible risks of vaccination. (5.6)

ADVERSE REACTIONS
Rates of injection site reactions (pain, redness, swelling) ranged from 10% to 53%, depending on reaction and dose number, and were highest following Doses 4 and 5. Fever was common (20% to 30%) following Doses 1-3. Other common solicited adverse reactions were drowsiness, irritability/fussiness, and loss of appetite, reported in approximately 15% to 60% of subjects, depending on reactions and dose number. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

DRUG INTERACTIONS
Do not mix INFANRIX with any other vaccine in the same syringe or vial. (7.1)
See 17 for PATIENT COUNSELING INFORMATION.

Revised: 11/2019
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE
INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the 7th birthday).
2 DOSAGE AND ADMINISTRATION

2.1 Preparation for Administration
Shake vigorously to obtain a homogeneous, turbid, white suspension. Do not use if resuspension does not occur with vigorous shaking. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.

For the prefilled syringes, attach a sterile needle and administer intramuscularly.

For the vials, use a sterile needle and sterile syringe to withdraw the 0.5-mL dose and administer intramuscularly. Changing needles between drawing vaccine from a vial and injecting it into a recipient is not necessary unless the needle has been damaged or contaminated. Use a separate sterile needle and syringe for each individual.

Do not administer this product intravenously, intradermally, or subcutaneously.

2.2 Dose and Schedule
A 0.5-mL dose of INFANRIX is approved for intramuscular administration in infants and children aged 6 weeks through 6 years (prior to the 7th birthday) as a 5-dose series. The series consists of a primary immunization course of 3 doses administered at 2, 4, and 6 months of age (at intervals of 4 to 8 weeks), followed by 2 booster doses, administered at 15 to 20 months of age and at 4 to 6 years of age. The first dose may be given as early as 6 weeks of age.

The preferred administration site is the anterolateral aspect of the thigh for most infants aged younger than 12 months and the deltoid muscle of the upper arm for most children aged 12 months through 6 years.

2.3 Use of INFANRIX with Other DTaP Vaccines
Sufficient data are not available on the safety and effectiveness of interchanging INFANRIX and Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccines from different manufacturers for successive doses of the DTaP vaccination series. Because the pertussis antigen components of INFANRIX and PEDIARIX [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] are the same, INFANRIX may be used to complete a DTaP vaccination series initiated with PEDIARIX.

2.4 Additional Dosing Information
If any recommended dose of pertussis vaccine cannot be given [see Contraindications (4.2, 4.3), Warnings and Precautions (5.5)], Diphtheria and Tetanus Toxoids Adsorbed (DT) For Pediatric Use should be given according to its prescribing information.

3 DOSAGE FORMS AND STRENGTHS
INFANRIX is a suspension for injection available in 0.5-mL single-dose vials and 0.5-mL single-dose, prefilled TIPLOK syringes.

4 CONTRAINDICATIONS

4.1 Hypersensitivity
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or to any component of INFANRIX is a contraindication [see Description (11)]. Because of the uncertainty as to which component of the vaccine might be
responsible, no further vaccination with any of these components should be given. Alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is being considered.

4.2 Encephalopathy
Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including INFANRIX.

4.3 Progressive Neurologic Disorder
Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy, is a contraindication to administration of any pertussis-containing vaccine, including INFANRIX. Pertussis vaccine should not be administered to individuals with these conditions until a treatment regimen has been established and the condition has stabilized.

5 WARNINGS AND PRECAUTIONS

5.1 Guillain-Barré Syndrome
If Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give any tetanus toxoid-containing vaccine, including INFANRIX, should be based on careful consideration of the potential benefits and possible risks. When a decision is made to withhold tetanus toxoid, other available vaccines should be given, as indicated.

5.2 Latex
The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions.

5.3 Syncope
Syncope (fainting) can occur in association with administration of injectable vaccines, including INFANRIX. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.

5.4 Adverse Reactions following Prior Pertussis Vaccination
If any of the following reactions occur in temporal relation to receipt of a pertussis-containing vaccine, the decision to give any pertussis-containing vaccine, including INFANRIX, should be based on careful consideration of the potential benefits and possible risks:

- Temperature of ≥40.5°C (105°F) within 48 hours not due to another identifiable cause;
- Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours;
- Persistent, inconsolable crying lasting ≥3 hours, occurring within 48 hours;
- Seizures with or without fever occurring within 3 days.

5.5 Children at Risk for Seizures
For children at higher risk for seizures than the general population, an appropriate antipyretic may be administered at the time of vaccination with a pertussis-containing vaccine, including INFANRIX, and for the ensuing 24 hours to reduce the possibility of post-vaccination fever.

5.6 Apnea in Premature Infants
Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including INFANRIX, to infants born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination.

5.7 Preventing and Managing Allergic Vaccine Reactions
Prior to administration, the healthcare provider should review the patient’s immunization history for possible vaccine hypersensitivity. Epinephrine and other appropriate agents used for the control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur.

6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

Approximately 95,000 doses of INFANRIX have been administered in clinical studies. In these studies, 29,243 infants have received INFANRIX in primary series studies: 6,081 children have received a fourth consecutive dose of INFANRIX, 1,764 children have received a fifth consecutive dose of INFANRIX, and 559 children have received a dose of INFANRIX following 3 doses of PEDIARIX.

Solicited Adverse Reactions
In a U.S. study, 335 infants received INFANRIX, ENGERIX-B [Hepatitis B Vaccine (Recombinant)], inactivated poliovirus vaccine (IPV, Sanofi Pasteur SA), Haemophilus b (Hib) conjugate vaccine (Wyeth Pharmaceuticals Inc.), and pneumococcal 7-valent conjugate (PCV7) vaccine (Wyeth Pharmaceuticals Inc.) concomitantly at separate sites. All vaccines were administered at 2, 4, and 6 months of age. Data on solicited local reactions and general adverse reactions were collected by parents using standardized diary cards for 4 consecutive days following each vaccine dose (i.e., day of vaccination and the next 3 days) (Table 1). Among subjects, 69% were white, 16% were Hispanic, 8% were black, 4% were Asian, and 2% were of other racial/ethnic groups.

Table 1. Solicited Local and General Adverse Reactions (%) Occurring within 4 Days of Vaccination\textsuperscript{a} with Separate Concomitant Administration of INFANRIX, ENGERIX-B, IPV, Haemophilus b (Hib) Conjugate Vaccine, and Pneumococcal Conjugate Vaccine (PCV7) (Modified Intent-to-Treat Cohort)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>INFANRIX, ENGERIX-B, IPV, Hib Vaccine, &amp; PCV7</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose 1</td>
</tr>
<tr>
<td>Local\textsuperscript{b}</td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>335</td>
</tr>
<tr>
<td>Pain, any</td>
<td>32</td>
</tr>
<tr>
<td>Pain, Grade 2 or 3</td>
<td>9</td>
</tr>
<tr>
<td>Pain, Grade 3</td>
<td>3</td>
</tr>
<tr>
<td>Redness, any</td>
<td>18</td>
</tr>
<tr>
<td>Redness, &gt;20 mm</td>
<td>0</td>
</tr>
<tr>
<td>Swelling, any</td>
<td>10</td>
</tr>
<tr>
<td>Swelling, &gt;20 mm</td>
<td>1</td>
</tr>
<tr>
<td>General</td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>333</td>
</tr>
<tr>
<td>Fever\textsuperscript{c} (≥100.4°F)</td>
<td>20</td>
</tr>
</tbody>
</table>
Hib conjugate vaccine and PCV7 manufactured by Wyeth Pharmaceuticals Inc. IPV manufactured by Sanofi Pasteur SA.

Modified intent-to-treat cohort = All vaccinated subjects for whom safety data were available.

n = Number of infants for whom at least one symptom sheet was completed; for fever; numbers exclude missing temperature recordings or tympanic measurements.

Grade 2: Pain defined as cried/protested on touch; drowsiness defined as interfered with normal daily activities; irritability/fussiness defined as crying more than usual/interfered with normal daily activities; loss of appetite defined as eating less than usual/interfered with normal daily activities.

Grade 3: Pain defined as cried when limb was moved/spontaneously painful; drowsiness defined as prevented normal daily activities; irritability/fussiness defined as crying that could not be comforted/prevented normal daily activities; loss of appetite defined as no eating at all.

Within 4 days of vaccination defined as day of vaccination and the next 3 days.

Local reactions at the injection site for INFANRIX.

Axillary temperatures increased by 1°C and oral temperatures increased by 0.5°C to derive equivalent rectal temperature.

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Group Primed with INFANRIX</th>
<th>Group Primed with PEDIARIX</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 247</td>
<td>n = 553</td>
</tr>
<tr>
<td>Local</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain, any</td>
<td>45</td>
<td>48</td>
</tr>
<tr>
<td>Pain, Grade 2 or 3</td>
<td>19</td>
<td>19</td>
</tr>
</tbody>
</table>

In a U.S. study, the safety of a booster dose of INFANRIX was evaluated in children aged 15 to 18 months whose previous 3 DTaP doses were with INFANRIX (n = 251) or PEDIARIX (n = 559).

Vaccines administered concurrently with the fourth dose of INFANRIX included measles, mumps, and rubella (MMR) vaccine (Merck & Co., Inc.), varicella vaccine (Merck & Co., Inc.), pneumococcal 7-valent conjugate (PCV7) vaccine (Wyeth Pharmaceuticals Inc.), and any U.S.-licensed Hib conjugate vaccine; these were given concomitantly in 13.2%, 6.3%, 37.4%, and 41.2% of subjects, respectively.

Data on solicited adverse reactions were collected by parents using standardized diary cards for 4 consecutive days following each vaccine dose (i.e., day of vaccination and the next 3 days) (Table 2). Among subjects, 85% were white, 6% were Hispanic, 6% were black, 1% were Asian, and 2% were of other racial/ethnic groups.

Table 2. Solicited Local and General Adverse Reactions (%) Occurring within 4 Days of Vaccination\(^a\) with INFANRIX Administered as the Fourth Dose following 3 Previous Doses of INFANRIX or PEDIARIX (Total Vaccinated Cohort)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Group Primed with INFANRIX(^b)</th>
<th>Group Primed with PEDIARIX(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 247</td>
<td>n = 553</td>
</tr>
<tr>
<td>Local</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain, any</td>
<td>45</td>
<td>48</td>
</tr>
<tr>
<td>Pain, Grade 2 or 3</td>
<td>19</td>
<td>19</td>
</tr>
</tbody>
</table>
Total Vaccinated Cohort = All subjects who received a dose of study vaccine.  
n = Number of subjects for whom at least one symptom sheet was completed.  
Grade 2: Pain defined as cried/protested on touch; drowsiness defined as interfered with normal daily activities; irritability defined as crying more than usual/interfered with normal daily activities; loss of appetite defined as eating less than usual/no effect on normal daily activities.  
Grade 3: Pain defined as cried when limb was moved/spontaneously painful; drowsiness defined as prevented normal daily activities; irritability defined as crying that could not be comforted/prevented normal daily activities; loss of appetite defined as eating less than usual/interfered with normal daily activities.  
Within 4 days of vaccination defined as day of vaccination and the next 3 days.  
Received INFANRIX, ENGERIX-B, IPV (Sanofi Pasteur SA), PCV7 vaccine (Wyeth Pharmaceuticals Inc.), and Hib conjugate vaccine (Wyeth Pharmaceuticals Inc.) at 2, 4, and 6 months of age.  
Received PEDIARIX, PCV7 vaccine (Wyeth Pharmaceuticals Inc.), and Hib conjugate vaccine (Wyeth Pharmaceuticals Inc.) at 2, 4, and 6 months of age or PCV7 vaccine 2 weeks later.  
Local reactions at the injection site for INFANRIX.  
Axillary temperatures.  

<table>
<thead>
<tr>
<th>Pain, Grade 3</th>
<th>4</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Redness, any</td>
<td>48</td>
<td>50</td>
</tr>
<tr>
<td>Redness, &gt;20 mm</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Swelling, any</td>
<td>33</td>
<td>33</td>
</tr>
<tr>
<td>Swelling, &gt;20 mm</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Increase in mid-thigh circumference, any</td>
<td>33</td>
<td>26</td>
</tr>
<tr>
<td>Increase in mid-thigh circumference, &gt;40 mm</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

**General**

<table>
<thead>
<tr>
<th>Fever* (&gt;99.5°F)</th>
<th>9</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever* (&gt;100.4°F)</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Fever* (&gt;101.3°F)</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Drowsiness, any</td>
<td>36</td>
<td>31</td>
</tr>
<tr>
<td>Drowsiness, Grade 2 or 3</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>Drowsiness, Grade 3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Irritability, any</td>
<td>52</td>
<td>54</td>
</tr>
<tr>
<td>Irritability, Grade 2 or 3</td>
<td>18</td>
<td>20</td>
</tr>
<tr>
<td>Irritability, Grade 3</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Loss of appetite, any</td>
<td>25</td>
<td>23</td>
</tr>
<tr>
<td>Loss of appetite, Grade 2 or 3</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Loss of appetite, Grade 3</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

Total Vaccinated Cohort = All subjects who received a dose of study vaccine.  
n = Number of subjects for whom at least one symptom sheet was completed.  
Grade 2: Pain defined as cried/protested on touch; drowsiness defined as interfered with normal daily activities; irritability defined as crying more than usual/interfered with normal daily activities; loss of appetite defined as eating less than usual/no effect on normal daily activities.  
Grade 3: Pain defined as cried when limb was moved/spontaneously painful; drowsiness defined as prevented normal daily activities; irritability defined as crying that could not be comforted/prevented normal daily activities; loss of appetite defined as eating less than usual/interfered with normal daily activities.  
Within 4 days of vaccination defined as day of vaccination and the next 3 days.  
Received INFANRIX, ENGERIX-B, IPV (Sanofi Pasteur SA), PCV7 vaccine (Wyeth Pharmaceuticals Inc.), and Hib conjugate vaccine (Wyeth Pharmaceuticals Inc.) at 2, 4, and 6 months of age.  
Received PEDIARIX, PCV7 vaccine (Wyeth Pharmaceuticals Inc.), and Hib conjugate vaccine (Wyeth Pharmaceuticals Inc.) at 2, 4, and 6 months of age or PCV7 vaccine 2 weeks later.  
Local reactions at the injection site for INFANRIX.  
Axillary temperatures.  

In a U.S. study, the safety of a fifth consecutive dose of INFANRIX coadministered at separate sites with a fourth dose of IPV (Sanofi Pasteur SA) and a second dose of MMR vaccine (Merck & Co., Inc.) was evaluated in 1,053 children aged 4 to 6 years. Data on solicited adverse reactions were collected by parents using standardized diary cards for 4 consecutive days following each vaccine dose (i.e., day of vaccination and the next 3 days) (Table 3). Among subjects, 43% were white, 18% Hispanic, 15% Asian, 7% black, and 17% were of other racial/ethnic groups.

**Table 3. Solicited Local and General Adverse Reactions (%) Occurring within 4 Days of Vaccination**

<table>
<thead>
<tr>
<th>Local*</th>
<th>n = 1,039-1,043</th>
</tr>
</thead>
</table>
IPV manufactured by Sanofi Pasteur SA. MMR vaccine manufactured by Merck & Co., Inc.

Total Vaccinated Cohort = All vaccinated subjects for whom safety data were available.
n = Number of children with evaluable data for the reactions listed.

- Local reactions at the injection site for INFANRIX.
- Grade 2 defined as painful when the limb was moved; Grade 3 defined as preventing normal daily activities.
- Grade 3 defined as not eating at all.

<table>
<thead>
<tr>
<th>Reaction</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain, any</td>
<td>53</td>
</tr>
<tr>
<td>Pain, Grade 2 or 3(^c)</td>
<td>12</td>
</tr>
<tr>
<td>Pain, Grade 3(^c)</td>
<td>1</td>
</tr>
<tr>
<td>Redness, any</td>
<td>37</td>
</tr>
<tr>
<td>Redness, ≥50 mm</td>
<td>20</td>
</tr>
<tr>
<td>Redness, ≥110 mm</td>
<td>4</td>
</tr>
<tr>
<td>Arm circumference increase, any</td>
<td>38</td>
</tr>
<tr>
<td>Arm circumference increase, &gt;20 mm</td>
<td>7</td>
</tr>
<tr>
<td>Arm circumference increase, &gt;30 mm</td>
<td>3</td>
</tr>
<tr>
<td>Swelling, any</td>
<td>27</td>
</tr>
<tr>
<td>Swelling, ≥50 mm</td>
<td>12</td>
</tr>
<tr>
<td>Swelling, ≥110 mm</td>
<td>2</td>
</tr>
</tbody>
</table>

**General** \(n = 993-1,036\)

<table>
<thead>
<tr>
<th>Reaction</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drowsiness, any</td>
<td>18</td>
</tr>
<tr>
<td>Drowsiness, Grade 3(^d)</td>
<td>1</td>
</tr>
<tr>
<td>Fever, ≥99.5°F</td>
<td>15</td>
</tr>
<tr>
<td>Fever, &gt;100.4°F</td>
<td>4</td>
</tr>
<tr>
<td>Fever, &gt;102.2°F</td>
<td>1</td>
</tr>
<tr>
<td>Fever, &gt;104°F</td>
<td>0</td>
</tr>
<tr>
<td>Loss of appetite, any</td>
<td>16</td>
</tr>
<tr>
<td>Loss of appetite, Grade 3(^e)</td>
<td>1</td>
</tr>
</tbody>
</table>

In the U.S. booster immunization studies in which INFANRIX was administered as the fourth or fifth dose in the DTaP series following previous doses with INFANRIX or PEDIARIX, large swelling reactions of the limb injected with INFANRIX were assessed.

In the fourth-dose study, a large swelling reaction was defined as injection site swelling with a diameter of >50 mm, a >50 mm increase in the mid-thigh circumference compared with the pre-vaccination measurement, and/or any diffuse swelling that interfered with or prevented daily activities. The overall incidence of large swelling reactions occurring within 4 days (Day 0-Day 3) following INFANRIX was 2.3%.

In the fifth-dose study, a large swelling reaction was defined as swelling that involved >50% of the injected upper arm length and that was associated with a >30 mm increase in mid-upper arm circumference within 4 days following vaccination. The incidence of large swelling reactions following the fifth consecutive dose of INFANRIX was 1.0%.

**Less Common and Serious General Adverse Reactions**

Selected adverse reactions reported from a double-blind, randomized Italian clinical efficacy trial involving 4,696 children administered INFANRIX or 4,678 children administered whole-cell DTP vaccine (DTwP) (manufactured by Connaught Laboratories, Inc.) as a 3-dose primary series are shown in Table 4. The incidence of rectal temperature ≥104°F, hypotonic-hyporesponsive episodes, and
persistent crying ≥3 hours following administration of INFANRIX was significantly less than that following administration of whole-cell DTP vaccine.

Table 4. Selected Adverse Reactions Occurring within 48 Hours following Vaccination with INFANRIX or Whole-Cell DTP in Italian Infants at 2, 4, or 6 Months of Age

<table>
<thead>
<tr>
<th>Reaction</th>
<th>INFANRIX (n = 13,761 Doses)</th>
<th>Whole-Cell DTP Vaccine (n = 13,520 Doses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>Rate/1,000 Doses</td>
<td>Number</td>
</tr>
<tr>
<td>Fever (≥104°F)(^a,b)</td>
<td>5</td>
<td>0.36</td>
</tr>
<tr>
<td>Hypotonic-hyporesponsive episode(^c)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Persistent crying ≥3 hours(^a)</td>
<td>6</td>
<td>0.44</td>
</tr>
<tr>
<td>Seizures(^d)</td>
<td>1(^e)</td>
<td>0.07</td>
</tr>
</tbody>
</table>

\(^a\)P <0.001. 
\(^b\) Rectal temperatures. 
\(^c\)P = 0.002. 
\(^d\) Not statistically significant at P <0.05. 
\(^e\) Maximum rectal temperature within 72 hours of vaccination = 103.1°F. 
\(^f\) Maximum rectal temperature within 72 hours of vaccination = 99.5°F, 101.3°F, and 102.2°F.

In a German safety study that enrolled 22,505 infants (66,867 doses of INFANRIX administered as a 3-dose primary series at 3, 4, and 5 months of age), all subjects were monitored for unsolicited adverse events that occurred within 28 days following vaccination using report cards. In a subset of subjects (n = 2,457), these cards were standardized diaries which solicited specific adverse reactions that occurred within 8 days of each vaccination in addition to unsolicited adverse events which occurred from enrollment until approximately 30 days following the third vaccination. Cards from the whole cohort were returned at subsequent visits and were supplemented by spontaneous reporting by parents and a medical history after the first and second doses of vaccine. In the subset of 2,457, adverse events following the third dose of vaccine were reported via standardized diaries and spontaneous reporting at a follow-up visit. Adverse events in the remainder of the cohort were reported via report cards which were returned by mail approximately 28 days after the third dose of vaccine. Adverse reactions (rates per 1,000 doses) occurring within 7 days following any of the first 3 doses included: unusual crying (0.09), febrile seizure (0.0), afebrile seizure (0.13), and hypotonic-hyporesponsive episodes (0.01).

6.2 Postmarketing Experience

In addition to reports in clinical trials for INFANRIX, the following adverse reactions have been identified during postapproval use of INFANRIX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccination.

Infections and Infestations
Bronchitis, cellulitis, respiratory tract infection.

Blood and Lymphatic System Disorders
Lymphadenopathy, thrombocytopenia.

Immune System Disorders
Anaphylactic reaction, hypersensitivity.

Nervous System Disorders
Encephalopathy, headache, hypotonia, syncope.

Ear and Labyrinth Disorders
Ear pain.

Cardiac Disorders
Cyanosis.

Respiratory, Thoracic, and Mediastinal Disorders
Apnea, cough.

Skin and Subcutaneous Tissue Disorders
Angioedema, erythema, pruritus, rash, urticaria.

General Disorders and Administration Site Conditions
Fatigue, injection site induration, injection site reaction, Sudden Infant Death Syndrome.

7 DRUG INTERACTIONS

7.1 Concomitant Vaccine Administration
In clinical trials, INFANRIX was given concomitantly with Hib conjugate vaccine, pneumococcal 7-valent conjugate vaccine, hepatitis B vaccine, IPV, and the second dose of MMR vaccine [see Adverse Reactions (6.1), Clinical Studies (14.3)].

When INFANRIX is administered concomitantly with other injectable vaccines, they should be given with separate syringes. INFANRIX should not be mixed with any other vaccine in the same syringe or vial.

7.2 Immunosuppressive Therapies
Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to INFANRIX.

8 USE IN SPECIFIC POPULATIONS

8.4 Pediatric Use
Safety and effectiveness of INFANRIX in infants aged younger than 6 weeks and children aged 7 to 16 years have not been established. INFANRIX is not approved for use in these age groups.

11 DESCRIPTION
INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) is a noninfectious, sterile vaccine for intramuscular administration. Each 0.5-mL dose is formulated to contain 25 Lf of diphtheria toxoid, 10 Lf of tetanus toxoid, 25 mcg of inactivated pertussis toxin (PT), 25 mcg of filamentous hemagglutinin (FHA), and 8 mcg of pertactin (69 kiloDalton outer membrane protein).

The diphtheria toxin is produced by growing Corynebacterium diphtheriae (C. diphtheriae) in Fenton medium containing a bovine extract. Tetanus toxin is produced by growing Clostridium tetani (C. tetani) in a modified Latham medium derived from bovine casein. The bovine materials used in these extracts are sourced from countries which the United States Department of Agriculture (USDA) has determined neither have nor present an undue risk for bovine spongiform encephalopathy (BSE). Both toxins are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and...
The acellular pertussis antigens (PT, FHA, and pertactin) are isolated from *Bordetella pertussis* (*B. pertussis*) culture grown in modified Stainer-Scholte liquid medium. PT and FHA are isolated from the fermentation broth; pertactin is extracted from the cells by heat treatment and flocculation. The antigens are purified in successive chromatographic and precipitation steps. PT is detoxified using glutaraldehyde and formaldehyde. FHA and pertactin are treated with formaldehyde.

Diphtheria and tetanus toxoids and pertussis antigens (PT, FHA, and pertactin) are individually adsorbed onto aluminum hydroxide.

Diphtheria and tetanus toxoid potency is determined by measuring the amount of neutralizing antitoxin in previously immunized guinea pigs. The potency of the acellular pertussis components (PT, FHA, and pertactin) is determined by enzyme-linked immunosorbent assay (ELISA) on sera from previously immunized mice.

Each 0.5-mL dose contains aluminum hydroxide as adjuvant (not more than 0.625 mg aluminum by assay) and 4.5 mg of sodium chloride. Each dose also contains ≤100 mcg of residual formaldehyde and ≤100 mcg of polysorbate 80 (Tween 80).

INFANRIX is available in vials and prefilled syringes. The tip caps of the prefilled syringes contain natural rubber latex; the plungers are not made with natural rubber latex. The vial stoppers are not made with natural rubber latex.

INFANRIX is formulated without preservatives.

**12 CLINICAL PHARMACOLOGY**

**12.1 Mechanism of Action**

**Diphtheria**

Diphtheria is an acute toxin-mediated infectious disease caused by toxigenic strains of *C. diphtheriae*. Protection against disease is due to the development of neutralizing antibodies to the diphtheria toxin. A serum diphtheria antitoxin level of 0.01 IU/mL is the lowest level giving some degree of protection; a level of 0.1 IU/mL is regarded as protective.1

**Tetanus**

Tetanus is an acute toxin-mediated infectious disease caused by a potent exotoxin released by *C. tetani*. Protection against disease is due to the development of neutralizing antibodies to the tetanus toxin. A serum tetanus antitoxin level of at least 0.01 IU/mL, measured by neutralization assays, is considered the minimum protective level.2,3 A level of 0.1 IU/mL is considered protective.4

**Pertussis**

Pertussis (whooping cough) is a disease of the respiratory tract caused by *B. pertussis*. The role of the different components produced by *B. pertussis* in either the pathogenesis of, or the immunity to, pertussis is not well understood. There is no well-established serological correlate of protection for pertussis.

**13 NONCLINICAL TOXICOLOGY**

**13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

INFANRIX has not been evaluated for carcinogenic or mutagenic potential or for impairment of fertility.

**14 CLINICAL STUDIES**
14.1 Diphtheria and Tetanus

Efficacy of diphtheria toxoid used in INFANRIX was determined on the basis of immunogenicity studies. A VERO cell toxin-neutralizing test confirmed the ability of infant sera (N = 45), obtained one month after a 3-dose primary series, to neutralize diphtheria toxin. Levels of diphtheria antitoxin ≥0.01 IU/mL were achieved in 100% of the sera tested.

Efficacy of tetanus toxoid used in INFANRIX was determined on the basis of immunogenicity studies. An in vivo mouse neutralization assay confirmed the ability of infant sera (N = 45), obtained 1 month after a 3-dose primary series, to neutralize tetanus toxin. Levels of tetanus antitoxin ≥0.01 IU/mL were achieved in 100% of the sera tested.

14.2 Pertussis

Efficacy of a 3-dose primary series of INFANRIX has been assessed in 2 clinical studies.

A double-blind, randomized, active Diphtheria and Tetanus Toxoids (DT)-controlled trial conducted in Italy assessed the absolute protective efficacy of INFANRIX when administered at 2, 4, and 6 months of age. The population used in the primary analysis of the efficacy of INFANRIX included 4,481 infants vaccinated with INFANRIX and 1,470 DT vaccinees. The mean length of follow-up was 17 months, beginning 30 days after the third dose of vaccine. After 3 doses, the absolute protective efficacy of INFANRIX against WHO-defined typical pertussis (21 days or more of paroxysmal cough with infection confirmed by culture and/or serologic testing) was 84% (95% CI: 76, 89). When the definition of pertussis was expanded to include clinically milder disease with respect to type and duration of cough, with infection confirmed by culture and/or serologic testing, the efficacy of INFANRIX was calculated to be 71% (95% CI: 60, 78) against >7 days of any cough and 73% (95% CI: 63, 80) against ≥14 days of any cough. Vaccine efficacy after 3 doses and with no booster dose in the second year of life was assessed in 2 subsequent follow-up periods. A follow-up period from 24 months to a mean age of 33 months was conducted in a partially unblinded cohort (children who received DT were offered pertussis vaccine and those who declined were retained in the study cohort). During this period, the efficacy of INFANRIX against WHO-defined pertussis was 78% (95% CI: 62, 87). During the third follow-up period, which was conducted in an unblinded manner among children aged 3 to 6 years, the efficacy of INFANRIX against WHO-defined pertussis was 86% (95% CI: 79, 91). Thus, protection against pertussis in children administered 3 doses of INFANRIX in infancy was sustained to 6 years of age.

A prospective efficacy trial was also conducted in Germany employing a household contact study design. In preparation for this study, 3 doses of INFANRIX were administered at 3, 4, and 5 months of age to more than 22,000 children living in 6 areas of Germany in a safety and immunogenicity study. Infants who did not participate in the safety and immunogenicity study could have received a DTwP vaccine or DT vaccine. Index cases were identified by spontaneous presentation to a physician. Households with at least one other member (i.e., besides index case) aged 6 through 47 months were enrolled. Household contacts of index cases were monitored for incidence of pertussis by a physician who was blinded to the vaccination status of the household. Calculation of vaccine efficacy was based on attack rates of pertussis in household contacts classified by vaccination status. Of the 173 household contacts who had not received a pertussis vaccine, 96 developed WHO-defined pertussis, as compared with 7 of 112 contacts vaccinated with INFANRIX. The protective efficacy of INFANRIX was calculated to be 89% (95% CI: 77, 95), with no indication of waning of protection up until the time of the booster vaccination. The average age of infants vaccinated with INFANRIX at the end of follow-up in this trial was 13 months (range: 6 to 25 months). The definition of pertussis was expanded to include clinically milder disease, with infection confirmed by culture and/or serologic testing, the efficacy of INFANRIX against ≥7 days of any cough was 67% (95% CI: 52, 78) and against ≥7 days of paroxysmal cough was 81% (95% CI: 68, 89). The corresponding efficacy of INFANRIX against ≥14 days of any cough or paroxysmal cough were 73% (95% CI: 59, 82) and 84% (95% CI: 71, 91), respectively.
Pertussis Immune Response to INFANRIX Administered as a 3-Dose Primary Series

The immune responses to each of the 3 pertussis antigens contained in INFANRIX were evaluated in sera obtained 1 month after the third dose of vaccine in each of 3 studies (schedule of administration: 2, 4, and 6 months of age in the Italian efficacy study and one U.S. study; 3, 4, and 5 months of age in the German efficacy study). One month after the third dose of INFANRIX, the response rates to each pertussis antigen were similar in all 3 studies. Thus, although a serologic correlate of protection for pertussis has not been established, the antibody responses to these 3 pertussis antigens (PT, FHA, and pertactin) in a U.S. population were similar to those achieved in 2 populations in which efficacy of INFANRIX was demonstrated.

14.3 Immune Response to Concomitantly Administered Vaccines

In a U.S. study, INFANRIX was given concomitantly, at separate sites, with Hib conjugate vaccine (Sanofi Pasteur SA) at 2, 4, and 6 months of age. Subjects also received ENGERIX-B and oral poliovirus vaccine (OPV). One month after the third dose of Hib conjugate vaccine, 90% of 72 infants had anti-PRP (polyribosyl-ribitol-phosphate) ≥1.0 mcg/mL.

In a U.S. study, INFANRIX was given concomitantly, at separate sites, with ENGERIX-B, IPV (Sanofi Pasteur SA), pneumococcal 7-valent conjugate (PCV7), and Hib conjugate vaccines (Wyeth Pharmaceuticals Inc.) at 2, 4, and 6 months of age. Immune responses were measured in sera obtained approximately 1 month after the third dose of vaccines. Among 121 subjects who had not received a birth dose of hepatitis B vaccine, 99.2% had anti-HBsAg (hepatitis B surface antigen) ≥10 mIU/mL following the third dose of ENGERIX-B. Among 153 subjects, 100% had anti-poliovirus 1, 2, and 3, ≥1:8 following the third dose of IPV. Although serological correlates for protection have not been established for the pneumococcal serotypes, a threshold level of ≥0.3 mcg/mL was evaluated. Following the third dose of PCV7 vaccine, 91.8% to 99.4% of subjects (n = 146-156) had anti-pneumococcal polysaccharide ≥0.3 mcg/mL for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 73.0% had a level ≥0.3 mcg/mL for serotype 6B.

15 REFERENCES


16 HOW SUPPLIED/STORAGE AND HANDLING

INFANRIX is available in 0.5-mL single-dose vials and 0.5-mL single-dose, disposable, prefilled TIPLOK syringes (packaged without needles):

NDC 58160-810-01 Vial in Package of 10: NDC 58160-810-11
NDC 58160-810-43 Syringe in Package of 10: NDC 58160-810-52

Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze. Discard if the vaccine has been frozen.
17 PATIENT COUNSELING INFORMATION

Provide the following information to the parent or guardian:

• Inform of the potential benefits and risks of immunization with INFANRIX, and of the importance of completing the immunization series.
• Inform about the potential for adverse reactions that have been temporally associated with administration of INFANRIX or other vaccines containing similar components.
• Instruct to report any adverse events to their healthcare provider.
• Give the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).

ENGEX-B, INFANRIX, PEDIARIX, and TIP-LOK are trademarks owned by or licensed to the GSK group of companies.

Manufactured by GlaxoSmithKline Biologicals
Rixensart, Belgium, U.S. License 1617

GSK Vaccines GmbH
Marburg, Germany, U.S. License 1617
Distributed by GlaxoSmithKline
Research Triangle Park, NC 27709
©2019 GSK group of companies or its licensor.
INF:29PI

PRINCIPAL DISPLAY PANEL
NDC 58160-810-11
INFANRIX
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
DTaP
Rx only
For Use from 6 Weeks to 7 Years of Age
10 x 0.5 mL Single-Dose Vials
GSK
Made in Belgium
©2019 GSK group of companies or its licensor.
Rev. 3/19
496035
INFANRIX

diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed suspension

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:58160-810</th>
</tr>
</thead>
<tbody>
<tr>
<td>VACCINE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Route of Administration | INTRAMUSCULAR |

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: K3WIN8YP13) (CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:K3WIN8YP13)</td>
<td>CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td>10 [iU] in 0.5 mL</td>
</tr>
<tr>
<td>CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: BR61QN26H) (CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:BR61QN26H)</td>
<td>CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td>25 [iU] in 0.5 mL</td>
</tr>
<tr>
<td>BORDETELLA PERTUSSIS TOXOID ANTIAGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED) (UNII: QSN5XO8ZSU) (BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED) - UNII:QSN5XO8ZSU)</td>
<td>BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED)</td>
<td>25 ug in 0.5 mL</td>
</tr>
<tr>
<td>BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: B3671Y4EY) (BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:B3671Y4EY)</td>
<td>BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td>25 ug in 0.5 mL</td>
</tr>
<tr>
<td>BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: B5O535NV6) (BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:B5O535NV6)</td>
<td>BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td>8 ug in 0.5 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALUMINUM HYDROXIDE (UNII: 5QBOT2IUN0)</td>
<td></td>
</tr>
<tr>
<td>FORMALDEHYDE (UNII: 1HG84L3525)</td>
<td></td>
</tr>
</tbody>
</table>
## Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:58160-810-11</td>
<td>10 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:58160-810-01</td>
<td>0.5 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:58160-810-52</td>
<td>10 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:58160-810-43</td>
<td>0.5 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLA</td>
<td>BLA103647</td>
<td>07/24/2009</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - GlaxoSmithKline Biologicals SA (372748392)

Revised: 11/2019

GlaxoSmithKline Biologicals SA